STERIS plc announced a quarterly dividend increase to $0.63 per share, marking 20 years of consecutive growth.
Quiver AI Summary
STERIS plc announced a quarterly interim dividend of $0.63 per share, reflecting a $0.06 increase and marking the 20th consecutive year of dividend growth for the company. The dividend will be payable on September 26, 2025, to shareholders recorded as of September 4, 2025. STERIS, a global leader in healthcare and life sciences, emphasizes infection prevention and aims to create a healthier and safer world through its products and services. The press release also includes cautionary information regarding forward-looking statements, highlighting potential risks and uncertainties that may affect STERIS's performance and operations, such as operating costs, regulatory compliance, and economic factors.
Potential Positives
- STERIS announced a quarterly interim dividend of $0.63 per share, reflecting a $0.06 increase, demonstrating the Company's commitment to returning value to shareholders.
- This marks the 20th consecutive year of dividend growth for STERIS, indicating a strong track record of financial performance and stability.
- The dividend is scheduled for payment on September 26, 2025, enhancing investor confidence and attracting potential investors looking for reliable dividend returns.
Potential Negatives
- Potential risks related to integration of acquired businesses that could impact profitability and operational effectiveness.
- Ongoing challenges regarding pricing pressures and customer retention that could erode profit margins.
- Uncertainties surrounding compliance with changing tax laws and regulations that may increase tax liabilities for the company.
FAQ
What is the amount of the quarterly dividend announced by STERIS?
STERIS announced a quarterly interim dividend of $0.63 per share.
When will the dividend be payable to shareholders?
The dividend is payable on September 26, 2025, to shareholders of record on September 4, 2025.
How many years of dividend growth has STERIS achieved?
STERIS has achieved 20 consecutive years of dividend growth.
Where can I find tax information regarding STERIS dividends?
Additional tax information about dividends is available at www.steris-ir.com.
Who can I contact for investor relations at STERIS?
For investor relations, you can contact Julie Winter at [email protected] or +1.440.392.7245.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STE Congressional Stock Trading
Members of Congress have traded $STE stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $STE stock by members of Congress over the last 6 months:
- REPRESENTATIVE APRIL MCCLAIN DELANEY sold up to $15,000 on 06/26.
- REPRESENTATIVE ROBERT BRESNAHAN purchased up to $15,000 on 02/25.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$STE Insider Trading Activity
$STE insiders have traded $STE stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $STE stock by insiders over the last 6 months:
- DANIEL A CARESTIO (President and CEO) has made 0 purchases and 3 sales selling 17,626 shares for an estimated $4,275,338.
- CARY L MAJORS (SVP and President, Healthcare) has made 0 purchases and 2 sales selling 12,828 shares for an estimated $3,208,025.
- JOHN ADAM ZANGERLE (Sr. VP, Gen Counsel, and Sec.) has made 0 purchases and 2 sales selling 1,978 shares for an estimated $477,581.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$STE Hedge Fund Activity
We have seen 381 institutional investors add shares of $STE stock to their portfolio, and 350 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WCM INVESTMENT MANAGEMENT, LLC removed 2,405,472 shares (-53.4%) from their portfolio in Q2 2025, for an estimated $577,842,483
- ORBIS ALLAN GRAY LTD added 1,544,011 shares (+inf%) to their portfolio in Q1 2025, for an estimated $349,950,093
- IMPAX ASSET MANAGEMENT GROUP PLC removed 951,758 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $215,715,950
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 540,999 shares (+55.2%) to their portfolio in Q1 2025, for an estimated $122,617,423
- POINT72 ASSET MANAGEMENT, L.P. added 458,022 shares (+inf%) to their portfolio in Q1 2025, for an estimated $103,810,686
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 452,146 shares (+9.1%) to their portfolio in Q1 2025, for an estimated $102,478,890
- GAMMA INVESTING LLC removed 407,811 shares (-99.4%) from their portfolio in Q2 2025, for an estimated $97,964,358
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$STE Analyst Ratings
Wall Street analysts have issued reports on $STE in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 07/15/2025
- JMP Securities issued a "Market Outperform" rating on 05/16/2025
- Stephens & Co. issued a "Overweight" rating on 05/15/2025
- Piper Sandler issued a "Overweight" rating on 02/03/2025
To track analyst ratings and price targets for $STE, check out Quiver Quantitative's $STE forecast page.
$STE Price Targets
Multiple analysts have issued price targets for $STE recently. We have seen 8 analysts offer price targets for $STE in the last 6 months, with a median target of $265.0.
Here are some recent targets:
- Brett Fishbin from Keybanc set a target price of $288.0 on 07/22/2025
- Patrick Wood from Morgan Stanley set a target price of $276.0 on 07/15/2025
- David Windley from Jefferies set a target price of $263.0 on 05/29/2025
- David Turkaly from JMP Securities set a target price of $280.0 on 05/16/2025
- Steven Etoch from Stephens & Co. set a target price of $250.0 on 05/15/2025
- Jason Bednar from Piper Sandler set a target price of $265.0 on 02/03/2025
Full Release
DUBLIN, IRELAND, July 30, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.63 per share. This represents a $0.06 increase in the dividend and the Company’s 20 th consecutive year of dividend growth. The dividend is payable on September 26, 2025, to shareholders of record at the close of business on September 4, 2025.
Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com.
STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe.
Company Contact:
Julie Winter, Vice President, Investor Relations and Corporate Communications
+1.440.392.7245
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This release may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “orders,” “backlog,” “comfortable,” “trend,” and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology.
Many factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, those identified in STERIS’s recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: (a) operating costs, pressure on pricing (including, without limitation, as a result of inflation), Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, Customers, clients or suppliers) being greater than expected and leading to erosion of profit margins; (b) STERIS’s ability to successfully integrate acquired businesses into its existing businesses, including unknown or inestimable liabilities, impairments, or increases in expected integration costs or difficulties in connection with the integration of such businesses; (c) changes in tax laws or interpretations or the adoption of certain income tax treaties in jurisdictions where we operate that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes, or tariffs and/or other trade barriers; (d) the possibility that compliance with laws, court rulings, certifications, regulations, or other regulatory actions, or the outcome of any pending or threatened litigation, including the Isomedix litigation, may delay, limit or prevent new product or service introductions, impact production, supply and/or marketing of existing products or services, result in uncovered costs, or otherwise affect STERIS’s performance, results, prospects or value; (e) the potential of international unrest, including military conflicts, economic downturn and effects of currency fluctuations; (f) the possibility of delays in receipt of orders, order cancellations, or the manufacture or shipment of ordered products; (g) the possibility that anticipated growth, performance or other results may not be achieved, or that timing, execution, impairments, or other issues associated with STERIS’s businesses, industry or initiatives may adversely impact STERIS’s performance, results, prospects or value; (h) the impact on STERIS and its operations of any legislation, regulations or orders, including but not limited to any new trade, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto by non-U.S. governments; (i) the possibility that anticipated financial results, anticipated revenue, productivity improvements, cost savings, growth synergies, and other anticipated benefits of acquisitions, restructuring efforts, and divestitures will not be realized or will be less than anticipated; (j) the level of STERIS’s indebtedness limiting financial flexibility or increasing future borrowing costs; (k) the effects of changes in credit availability and pricing, as well as the ability of STERIS and STERIS’s Customers and suppliers to adequately access the credit markets, on favorable terms or at all, when needed; (l) the impacts of increasing competition within our industry, which may exert pressure on our pricing strategy or lead to decreasing demand for our products and services; (m) the effects on our operations resulting from labor-related issues, such as strikes, unsuccessful union negotiations and other workforce disruptions; (n) the possibility of economic downturns and recessions, which could negatively impact our business by reducing consumer and Customer spending. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized.